Zobrazeno 1 - 10
of 144
pro vyhledávání: '"Jing-Quan Wang"'
Autor:
Xuan-Yu Chen, Zhuo-Xun Wu, Jing-Quan Wang, Qiu-Xu Teng, Hailin Tang, Qianwen Liu, Zhe-Sheng Chen, Wenkuan Chen
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
The therapeutic effect of chemotherapy and targeted therapy are known to be limited by drug resistance. Substantial evidence has shown that ATP-binding cassette (ABC) transporters P-gp and BCRP are significant contributors to multidrug resistance (MD
Externí odkaz:
https://doaj.org/article/5b33008691864d0b841b93d90e0769ec
Autor:
Yuval Bin Kanner, Qiu-Xu Teng, Assaf Ganoth, Dan Peer, Jing-Quan Wang, Zhe-Sheng Chen, Yossi Tsfadia
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Cancer is one of the leading causes of death worldwide, and the development of resistance to chemotherapy drugs is a major challenge in treating malignancies. In recent years, researchers have focused on understanding the mechanisms of multidrug resi
Externí odkaz:
https://doaj.org/article/40ab2f3d41d3461eaff5df8f603a74e4
The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells
Autor:
Hai-Ling Gao, Qingbin Cui, Jing-Quan Wang, Charles R. Ashby, Yanchun Chen, Zhi-Xin Shen, Zhe-Sheng Chen
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: The overexpression of ATP-binding cassette (ABC) transporters, ABCB1 and ABCG2, are two of the major mediators of multidrug resistance (MDR) in cancers. Although multiple ABCB1 and ABCG2 inhibitors have been developed and some have unde
Externí odkaz:
https://doaj.org/article/b3931dbcbd2048c398cc1269d077d2a0
Autor:
Zhuo-Xun Wu, Qiu-Xu Teng, Yuqi Yang, Nikita Acharekar, Jing-Quan Wang, Min He, Sabesan Yoganathan, Jun Lin, Jian Wang, Zhe-Sheng Chen
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 12, Iss 5, Pp 2609-2618 (2022)
Overexpression of ABCG2 transporter in cancer cells has been linked to the development of multidrug resistance (MDR), an obstacle to cancer therapy. Our recent study uncovered that the MET inhibitor, tepotinib, is a potent reversal agent for ABCB1-me
Externí odkaz:
https://doaj.org/article/290b0cda90f24d6583e11b6b86866a8c
Autor:
Kaijian Hou, Zhuo-Xun Wu, Xuan-Yu Chen, Jing-Quan Wang, Dongya Zhang, Chuanxing Xiao, Dan Zhu, Jagadish B. Koya, Liuya Wei, Jilin Li, Zhe-Sheng Chen
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 7, Iss 1, Pp 1-28 (2022)
Abstract The role of microbiota in health and diseases is being highlighted by numerous studies since its discovery. Depending on the localized regions, microbiota can be classified into gut, oral, respiratory, and skin microbiota. The microbial comm
Externí odkaz:
https://doaj.org/article/840bb506acaf4974bcf1db66dfaf1c8f
Autor:
Yuqi Yang, Qiu-Xu Teng, Zhuo-Xun Wu, Jing-Quan Wang, Zi-Ning Lei, Sabrina Lusvarghi, Suresh V. Ambudkar, Ning Ji, Zhe-Sheng Chen
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-6 (2022)
Highlights ABCB1 overexpression significantly desensitized both drug-selected and gene-transfected cells, which overexpress ABCB1, to OTS964 and that this drug resistance can be antagonized by verapamil, a known ABCB1 inhibitor. Consistently, a simil
Externí odkaz:
https://doaj.org/article/406c24e5b9104f00acdc1bc578a5b053
Autor:
Jing‐Quan Wang, Qingbin Cui, Zi‐Ning Lei, Qiu‐Xu Teng, Ning Ji, Lusheng Lin, Zhijun Liu, Zhe‐Sheng Chen
Publikováno v:
MedComm, Vol 2, Iss 2, Pp 221-235 (2021)
Abstract ATP‐binding cassette (ABC) transporters superfamily mediates multidrug resistance in cancer by extruding structurally distinct chemotherapeutic agents, causing failure in chemotherapy. Among the 49 ABC transporters, multidrug resistance pr
Externí odkaz:
https://doaj.org/article/aa7478f51fa24bd1aa772447a85498d1
Autor:
Lei Zhang, Biwei Ye, Yunfeng Lin, Yi-Dong Li, Jing-Quan Wang, Zhuo Chen, Feng-Feng Ping, Zhe-Sheng Chen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The efficacy of cancer chemotherapy can be attenuated or abrogated by multidrug resistance (MDR) in cancer cells. In this study, we determined the effect of the CDK4/6 inhibitor, ribociclib (or LEE011), on P-glycoprotein (P-gp)-mediated MDR in the hu
Externí odkaz:
https://doaj.org/article/3350ff2527c94e0a8abe397f724eb029
Autor:
Shao-Jia Qiang, Yu-Qi Shi, Tong-Yu Wu, Jing-Quan Wang, Xue-Lian Chen, Jie Su, Xin-Ping Chen, Jia-Zhong Li, Zhe-Sheng Chen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Stroke is the second leading cause of death worldwide and the leading cause of long-term disability that seriously endangers health and quality of human life. Tissue-type fibrinogen activator is currently the only drug approved by FDA for the treatme
Externí odkaz:
https://doaj.org/article/77f71744fbc3415c8e7eb44e9bb80ff1
Autor:
Xing-Duo Dong, Meng Zhang, Chao-Yun Cai, Qiu-Xu Teng, Jing-Quan Wang, Yi-Ge Fu, Qingbin Cui, Ketankumar Patel, Dong-Tao Wang, Zhe-Sheng Chen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The KRAS-G12C inhibitor ARS-1620, is a novel specific covalent inhibitor of KRAS-G12C, possessing a strong targeting inhibitory effect on KRAS-G12C mutant tumors. Overexpression of ATP-binding cassette super-family B member 1 (ABCB1/P-gp) is one of t
Externí odkaz:
https://doaj.org/article/a06b350b27f64a4eb5eb02d4b307d432